Novavax, Inc. NVAX
9.98 USD -0.22 (-2.16%)
At closeNov 11, 2026, 4:00 PM EST
9.98 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
9.90 Day range 10.36
6.20 52-week range 13.39
- YTD
- +48.51%
- 1 year
- +38.61%
News
prnewswire.com Novavax to Participate in Jefferies London Healthcare Conference GAITHERSBURG, Md., Nov. 11, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conference: Jefferies London…
zacks.com Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
zacks.com NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline Novavax shares fall 8% despite Q3 earnings and revenue beat as costs decline, while a Sanofi milestone drives a sharp increase in its 2026 outlook.
benzinga.com B. Riley Securities Reiterates Buy on Novavax, Lowers Price Target to $16 B. Riley Securities analyst Mayank Mamtani reiterates Novavax (NASDAQ:NVAX) with a Buy and lowers the price target from $18 to $16.
marketbeat.com Novavax Q3 Earnings Call Highlights Novavax NASDAQ: NVAX raised its 2026 revenue framework after partner Sanofi began a late-stage trial of a combination influenza and COVID-19 vaccine in Europe, triggering a $125 million milestone…
seekingalpha.com Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript Novavax, Inc. (NVAX) Q3 2026 Earnings Call Transcript
zacks.com Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates Novavax (NVAX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.62 per share a year ago.
benzinga.com Novavax Raises FY2026 Sales Guidance from $235.000M-$275.000M to $385.000M-$415.000M vs $380.285M Est Novavax (NASDAQ:NVAX) raises FY2026 sales outlook from $235.000 million-$275.000 million to $385.000 million-$415.000 million vs $380.285 million estimate.
prnewswire.com Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights Reports total revenue of $68 million for the third quarter of 2026 Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D…
benzinga.com Novavax Earns $125M Milestone Payment With Initiation Of Sanofi's Phase 3 Influence-COVID-19 Combination Vaccine Study Through Nuvaxovid Novavax (NASDAQ:NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax's…
benzinga.com Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push Shah Capital sells 2.87M Novavax (NVAX) shares for $32.6M, ends activist campaign, and shifts to a family office structure.
benzinga.com Citigroup Maintains Sell on Novavax, Raises Price Target to $8 Citigroup analyst Geoff Meacham maintains Novavax (NASDAQ:NVAX) with a Sell and raises the price target from $7 to $8.
benzinga.com Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…' Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.